hVIVO plc £6.3m HRV Contract Signed with Biotechnology Client
HVIVO plc £6.3m HRV Contract Signed with Biotechnology Client
Source: directorstalkinterviews.com
📰 Andrew Catchpole News
Andrew Catchpole News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Andrew Catchpole. Real-time updates on events, politics, business and more.
hVIVO plc £16.8m Full-Service RSV Contract with Top Five Global Pharma Client
HVIVO plc £16.8m Full-Service RSV Contract with Top Five Global Pharma Client
Source: directorstalkinterviews.com
UK human swine flu case: Why now, and what's next?
What you need to know about the first confirmed case of a new type of flu, found in North Yorkshire.
Source: bbc.co.uk
hVIVO hails success of influenza human challenge study
HVIVO PLC has hailed the success of an influenza human challenge study carried out at its specialist facilities in London. Researchers were able to...
Source: proactiveinvestors.co.uk
hVIVO plc report positive results from influenza human challenge study
HVIVO plc report positive results from influenza human challenge study
City Of United Kingdom Tower Hamlets Andrew Catchpole Venn Life Sciences Chronic Obstructive Pulmonary Disease
Source: directorstalkinterviews.com
HVIVO celebrates positive results for Pneumagen's Neumifil in trial
HVIVO PLC on Thursday noted Pneumagen Ltds report of successful clinical proof of concept for its broad-spectrum antiviral candidate Neumifil. hVIVO is a London-based specialist contract research...
Source: marketscreener.com
hVIVO plc £13.1m contract to develop an influenza B virus challenge model
HVIVO plc £13.1m contract to develop an influenza B virus challenge model
United Kingdom Yamin Mo Khan Andrew Catchpole Centers For Disease Good Manufacturing Practice United Kingdom Common Cold
Source: directorstalkinterviews.com
hVIVO secures first client of the new human metapneumovirus (hMPV) model
HVIVO secures first client of the new human metapneumovirus (hMPV) model
Source: directorstalkinterviews.com
HVIVO touts positive test results from seasonal flu drug, CD388
HVIVO PLC on Monday said that Cidara Therapeutics Inc has seen positive results from an ongoing study testing CD388, a drug designed to treat seasonal flu. hVIVO is a London-based specialist... | April 3, 2023
Source: marketscreener.com
Positive results from hVIVO study of Cidara flu candidate
Study demonstrated a reduction in viral replication in the upper respiratory tract as well as influenza infection - News - PharmaTimes
Source: pharmatimes.com